162 related articles for article (PubMed ID: 34774637)
1. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
Xu X; Nan Y
J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637
[No Abstract] [Full Text] [Related]
2. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
[TBL] [Abstract][Full Text] [Related]
3. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease].
Shi YW; Xiao QQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275
[TBL] [Abstract][Full Text] [Related]
4. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
Nan Y; An J; Bao J; Chen H; Chen Y; Ding H; Dou X; Duan Z; Fan J; Gao Y; Han T; Han Y; Hu P; Huang Y; Huang Y; Jia J; Jiang J; Jiang Y; Li J; Li J; Li R; Li S; Li W; Li Y; Lin S; Liu J; Liu S; Lu L; Lu Q; Luo X; Ma X; Rao H; Ren H; Ren W; Shang J; Shi L; Su M; Wang B; Wang R; Wei L; Wen Z; Wu B; Wu J; Xin S; Xing H; Xu J; Yan M; Yang J; Yang J; Yang L; Yang Y; Yu Y; Zhang L; Zhang L; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhao S; Zheng H; Zhou Y; Zhou Y; Zhuang H; Zuo W; Xu X; Qiao L
J Hepatol; 2021 Aug; 75(2):454-461. PubMed ID: 34019941
[TBL] [Abstract][Full Text] [Related]
5. Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) - April 2022 - AWMF Registration No.: 021-025.
;
Z Gastroenterol; 2022 Sep; 60(9):e733-e801. PubMed ID: 36100201
[No Abstract] [Full Text] [Related]
6. Advancing the global public health agenda for NAFLD: a consensus statement.
Lazarus JV; Mark HE; Anstee QM; Arab JP; Batterham RL; Castera L; Cortez-Pinto H; Crespo J; Cusi K; Dirac MA; Francque S; George J; Hagström H; Huang TT; Ismail MH; Kautz A; Sarin SK; Loomba R; Miller V; Newsome PN; Ninburg M; Ocama P; Ratziu V; Rinella M; Romero D; Romero-Gómez M; Schattenberg JM; Tsochatzis EA; Valenti L; Wong VW; Yilmaz Y; Younossi ZM; Zelber-Sagi S;
Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):60-78. PubMed ID: 34707258
[TBL] [Abstract][Full Text] [Related]
7. Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
Eslam M; George J
J Hepatol; 2020 Dec; 73(6):1575. PubMed ID: 32933781
[No Abstract] [Full Text] [Related]
8. PAKISTAN SOCIETY OF HEPATOLOGY (PSH) POSITION STATEMENT: RENAMING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) TO STEATOTIC LIVER DISEASE (SLD), ENDORSEMENT OF NEW MULTI-SOCIETY NOMENCLATURE.
Ali Z; Riaz M; Alam A; Faroqi JI
J Ayub Med Coll Abbottabad; 2023; 35(4):700-702. PubMed ID: 38406965
[No Abstract] [Full Text] [Related]
9. Real-World Implications of the American Gastroenterology Association Nonalcoholic Fatty Liver Disease Clinical Care Pathway in the US Adult Population.
Xu X; Alanaeme J; Wen Y; Colantonio LD; Muntner P; Long MT
Gastroenterology; 2023 Apr; 164(4):688-689.e4. PubMed ID: 36623777
[No Abstract] [Full Text] [Related]
10. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).
Vos MB; Abrams SH; Barlow SE; Caprio S; Daniels SR; Kohli R; Mouzaki M; Sathya P; Schwimmer JB; Sundaram SS; Xanthakos SA
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):319-334. PubMed ID: 28107283
[TBL] [Abstract][Full Text] [Related]
11. Foreword. Nonalcoholic Fatty Liver Disease.
Day CP; Anstee QM
Semin Liver Dis; 2015 Aug; 35(3):203-6. PubMed ID: 26378638
[No Abstract] [Full Text] [Related]
12. [Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].
Chinese Society of Hepatology, Chinese Medical Association
Zhonghua Gan Zang Bing Za Zhi; 2024 May; 32(5):418-434. PubMed ID: 38858192
[TBL] [Abstract][Full Text] [Related]
13. [Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology].
Caballería L; Saló J; Berzigotti A; Planas R; Vila C; Huertas C; Torres M; Torán P; Caballería J;
Gastroenterol Hepatol; 2014; 37(6):372-83. PubMed ID: 24746904
[No Abstract] [Full Text] [Related]
14. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.
Mendez-Sanchez N; Arrese M; Gadano A; Oliveira CP; Fassio E; Arab JP; Chávez-Tapia NC; Dirchwolf M; Torre A; Ridruejo E; Pinchemel-Cotrim H; Castellanos Fernández MI; Uribe M; Girala M; Diaz-Ferrer J; Restrepo JC; Padilla-Machaca M; Dagher L; Gatica M; Olaechea B; Pessôa MG; Silva M
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):65-72. PubMed ID: 33181118
[TBL] [Abstract][Full Text] [Related]
15. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.
Cotrim HP; Parise ER; Figueiredo-Mendes C; Galizzi-Filho J; Porta G; Oliveira CP
Arq Gastroenterol; 2016; 53(2):118-22. PubMed ID: 27305420
[TBL] [Abstract][Full Text] [Related]
16. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
Spearman CW; Desalegn H; Ocama P; Awuku YA; Ojo O; Elsahhar M; Abdo AA; Ndububa DA; Fouad Y; Borodo MM; Ng'wanasayi M; Ally R; Elwakil R
J Hepatol; 2021 May; 74(5):1256-1258. PubMed ID: 33484771
[No Abstract] [Full Text] [Related]
17. The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?
Fouad Y; Dufour JF; Zheng MH; Bollipo S; Desalegn H; Grønbaek H; Gish RG
Liver Int; 2022 Apr; 42(4):742-748. PubMed ID: 35182007
[TBL] [Abstract][Full Text] [Related]
18. Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
Brennan PN; Zelber-Sagi S; Allen AM; Dillon JF; Lazarus JV
Gut; 2024 Mar; 73(4):560-563. PubMed ID: 37898546
[No Abstract] [Full Text] [Related]
19. Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese.
Wong VW; Wong GL; Tse CH; Chan HL
J Hepatol; 2014 Sep; 61(3):708-9. PubMed ID: 24824280
[No Abstract] [Full Text] [Related]
20. Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
Eslam M; George J
J Hepatol; 2020 Nov; 73(5):1268-1269. PubMed ID: 32800588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
